The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 12, 2019
Filed:
Oct. 02, 2015
Ucb Biopharma Sprl, Brussels, BE;
Sanofi, Paris, FR;
Teresa De Haro Garcia, Slough, GB;
Michael Deligny, Brussels, BE;
Jag Paul Heer, Slough, GB;
Joanna Rachel Quincey, Slough, GB;
Mengyang Xuan, Slough, GB;
Zhaoning Zhu, Slough, GB;
Daniel Christopher Brookings, Slough, GB;
Mark Daniel Calmiano, Slough, GB;
Yves Evrard, Brussels, BE;
Martin Clive Hutchings, Slough, GB;
James Andrew Johnson, Slough, GB;
Sophie Jadot, Brussels, BE;
Jean Keyaerts, Brussels, BE;
Malcolm Mac Coss, Seabrook Island, SC (US);
Matthew Duncan Selby, Slough, GB;
Michael Alan Shaw, Slough, GB;
Dominique Louis Leon Swinnen, Brussels, BE;
Laurent Schio, Paris, FR;
Yann Foricher, Paris, FR;
Bruno Filoche-Romme, Paris, FR;
UCB Biopharma SPRL, Brussels, BE;
Abstract
A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.